QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 mersana-therapeutics-q1-2024-gaap-eps-016-beats-019-estimate-sales-9245m-beat-8500m-estimate

Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of ...

 jp-morgan-upgrades-mersana-therapeutics-to-neutral-announces-5-price-target

JP Morgan analyst Brian Cheng upgrades Mersana Therapeutics (NASDAQ:MRSN) from Underweight to Neutral and announces $5 price...

 why-butterfly-network-shares-are-trading-lower-by-22-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed four...

 hormel-foods-reports-upbeat-earnings-joins-pure-storage-okta-papa-johns-international-and-other-big-stocks-moving-higher-on-thursday

U.S. stocks were higher, with the Nasdaq Composite gaining around 50 points on Thursday.

 wedbush-upgrades-mersana-therapeutics-to-outperform-raises-price-target-to-7

Wedbush analyst David Nierengarten upgrades Mersana Therapeutics (NASDAQ:MRSN) from Neutral to Outperform and raises the pri...

 truist-securities-upgrades-mersana-therapeutics-to-buy-maintains-price-target-to-9

Truist Securities analyst Asthika Goonewardene upgrades Mersana Therapeutics (NASDAQ:MRSN) from Hold to Buy and maintains th...

 baird-maintains-neutral-on-mersana-therapeutics-raises-price-target-to-5

Baird analyst Colleen Kusy maintains Mersana Therapeutics (NASDAQ:MRSN) with a Neutral and raises the price target from $1 t...

 guggenheim-upgrades-mersana-therapeutics-to-buy-announces-7-price-target

Guggenheim analyst Michael Schmidt upgrades Mersana Therapeutics (NASDAQ:MRSN) from Neutral to Buy and announces $7 price ta...

 mersana-therapeutics-q4-eps-016-inline-sales-1070m-miss-1477m-estimate

Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.16) per share which met the analyst consensus estimate. Thi...

 earnings-scheduled-for-february-28-2024

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenu...

 why-keycorp-shares-are-trading-lower-by-over-5-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results...

 mersana-therapeutics-announces-business-updates-and-expected-2024-milestones

Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660, Dolasynthen B7-H4 ADC; exp...

 mersana-therapeutics-on-dec-15-co-and-merck-kgaa-mutually-agreed-to-terminate-collaboration-and-commercial-license-agreement-dated-june-23-2014-mutually-agreed-to-terminate-supply-agreement-dated-may-30-2018

-SEC Filing